XML 37 R22.htm IDEA: XBRL DOCUMENT v3.22.4
Revenues (Tables)
 12 Months Ended
Dec. 30, 2022
Revenue from Contract with Customer [Abstract]  
Schedule of Disaggregation of Revenue
Revenues consisted of the following (in thousands):
 Year Ended December 31,
 202220212020
Product revenues:
Gross product revenues
$1,951,169 $1,452,913 $962,591 
Discounts and allowances
(549,926)(375,657)(221,041)
Net product revenues1,401,243 1,077,256 741,550 
Collaboration revenues:
License revenues
162,056 249,956 167,295 
Collaboration services revenues
47,763 107,758 78,693 
Total collaboration revenues209,819 357,714 245,988 
Total revenues$1,611,062 $1,434,970 $987,538 
Net product revenues by product were as follows (in thousands):
Year Ended December 31,
202220212020
CABOMETYX
$1,375,909 $1,054,050 $718,687 
COMETRIQ
25,334 23,206 22,863 
Net product revenues
$1,401,243 $1,077,256 $741,550 
Schedule of Concentration Risks
The percentage of total revenues by customer who individually accounted for 10% or more of our total revenues were as follows:
 
Year Ended December 31,
 
202220212020
Affiliates of AmerisourceBergen Corporation18 %14 %11 %
Affiliates of McKesson Corporation17 %14 %12 %
Affiliates of CVS Health Corporation17 %14 %14 %
Ipsen Pharma SAS10 %21 %15 %
Accredo Health, Incorporated10 %9 %9 %
Affiliates of Optum Specialty Pharmacy10 %8 %11 %
As of December 31, 2022 and 2021, the percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows:
 
December 31,
 
20222021
Affiliates of McKesson Corporation22 %10 %
Ipsen Pharma SAS20 %50 %
Affiliates of AmerisourceBergen Corporation18 %11 %
Affiliates of CVS Health Corporation18 %9 %
Cardinal Health, Inc.11 %6 %
Schedule of Revenues Disaggregated by Geographic Region
Total revenues by geographic region were as follows (in thousands):
Year Ended December 31,
202220212020
U.S.
$1,413,743 $1,089,396 $752,890 
Europe
168,592 302,073 151,631 
Japan
28,727 43,501 83,017 
Total revenues
$1,611,062 $1,434,970 $987,538 
Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances
The activities and ending reserve balances for each significant category of discounts and allowances (which constitute variable consideration) were as follows (in thousands):
Chargebacks, Discounts for Prompt Payment and Other
Other Customer Credits/Fees and Co-pay Assistance
Rebates
Total
Balance at December 31, 2020
$9,853 $3,279 $17,404 $30,536 
Provision related to sales made in:
Current period243,119 30,728 100,361 374,208 
Prior periods(64)(111)1,624 1,449 
Payments and customer credits issued(238,283)(25,021)(94,564)(357,868)
Balance at December 31, 2021
14,625 8,875 24,825 48,325 
Provision related to sales made in:
Current period355,865 50,312 143,516 549,693 
Prior periods611 (169)(209)233 
Payments and customer credits issued(344,220)(44,094)(132,706)(521,020)
Balance at December 31, 2022
$26,881 $14,924 $35,426 $77,231 
Schedule of Other Assets and Other Liabilities
Contract assets and liabilities were as follows (in thousands):
 
December 31,
 
20222021
Contract assets(1)
$1,659 $1,665 
Contract liabilities:
Current portion(2)
$7,488 $7,814 
Long-term portion(3)
6,582 8,739 
Total contract liabilities$14,070 $16,553 
____________________
(1)    Presented in other long-term assets in the accompanying Consolidated Balance Sheets.
(2)    Presented in other current liabilities in the accompanying Consolidated Balance Sheets.
(3)    Presented in the long-term portion of deferred revenues in the accompanying Consolidated Balance Sheets.